North America Melanoma Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
USD
1,964.80 Million
USD
3,466.02 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,964.80 Million |
 Market Size (Forecast Year) |
USD 3,466.02 Million |
 CAGR |
% |
| Major Markets Players |
北美黑色素瘤癌症诊断市场，按产品类型（仪器、消耗品和配件等）、测试类型（生物标志物测试、影像测试、活检、荧光原位杂交 (FISH) 测试、比较基因组杂交 (CGH) 测试、免疫组织化学 (IHC) 测试等）、最终用户（医院、相关实验室、独立诊断实验室、诊断影像中心、癌症研究机构等）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测 2030。
北美黑色素瘤癌症诊断市场分析与洞察
全球对非侵入性检测方法的需求增加，增强了市场需求。为提供更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要市场参与者高度关注各种更快的诊断方法。此外，政府对黑色素瘤癌症诊断的举措也促进了黑色素瘤癌症诊断市场的需求增长。
市场参与者不断增加的医疗支出战略举措为市场带来了机遇。然而，新兴经济体缺乏熟练和认证的专业人员以及黑色素瘤诊断程序的高昂成本是市场增长面临的主要挑战。
北美黑色素瘤癌症诊断市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 7.4% 的复合年增长率增长，预计到 2030 年将从 2022 年的 19.648 亿美元达到 34.6602 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2020-1015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按产品类型（仪器、耗材及配件等）、测试类型（生物标志物测试、影像测试、活检、荧光原位杂交 (FISH) 测试、比较基因组杂交 (CGH) 测试、免疫组织化学 (IHC) 测试等）、最终用户（医院、相关实验室、独立诊断实验室、诊断影像中心、癌症研究机构等）、分销渠道（直接招标和零售销售） |
|
覆盖国家 |
美国、加拿大和墨西哥 |
|
涵盖的市场参与者 |
Nanostring、Thermo Fisher Scientific Inc.、Quest Diagnostics Incorporated、Agilent Technologies, Inc、QIAGEN、Inivata Ltd、F. Hoffman-La Roche Ltd、Abbott、AMLo Biosciences Limited、Myriad Genetics Genetics Inc、Castle Biosciences、DermTech、Michael Diagnostics Ltd、Damae Medical、Skin Analytics、DermLite、DermaSensor、Skyline Dx、Neracare GmbH、VERISKIN INC.、Illumina Inc 和 bioMerieux SA 等 |
市场定义
黑色素瘤癌症诊断是通过研究皮肤细胞和分子来识别黑色素瘤的过程。这些黑色素瘤癌症诊断是一种策略，借助实验室进行的各种测试来研究、分析和诊断某些细胞或分子。它专门用于测量特定的生物标志物或识别皮肤细胞中的生物标志物。黑色素瘤癌症诊断的目的是提供更有效的检测和更快的诊断。
黑色素瘤癌症诊断可帮助医生确定癌症分期，从而有效治疗不同阶段的患者。此外，由于具有临床实践潜力，多种测试可用于提供额外支持，以提高黑色素瘤癌症诊断的效率，主要市场参与者的存在也有助于市场增长。
北美黑色素瘤癌症诊断市场动态
驱动程序
-
早期黑色素瘤癌症诊断需求不断增长
黑色素瘤是一种可能致命的癌症，最常见于皮肤。北美黑色素瘤发病率显著上升。皮肤白皙和纬度较低的人群发病率最高。它是因病死亡平均损失年数最多的癌症之一。黑色素瘤发病率和死亡率上升，给个人和经济带来了沉重的负担。各种高风险地区都采取了预防措施，并取得了不同程度的成功。必须通过研究计划更好地了解疾病的起源和风险因素。
-
预防性健康检查的偏好日益增加
预防性健康检查是针对黑色素瘤癌症疾病的初步发现而采取的预防措施。此外，人们越来越倾向于进行预防性健康检查，这为未来可能接触任何疾病提供了保障。
提高筛查意识是预防黑色素瘤癌症最重要的组成部分。筛查包括癌症的识别和风险因素的检查，以在早期阶段限制损失。
机会
-
黑色素瘤癌症治疗的医疗支出增加
不断增长的医疗保健基础设施对市场来说是一个机遇，因为如果对医疗保健的投资增加，更多的人就会意识到癌症疾病，并诊断自己的健康状况以进行预防和治疗。
增加癌症治疗的医疗支出也有助于患者接受无忧的先进治疗，以便更好地诊断和治疗，从而快速康复。医疗支出由自付费用（人们支付自己的医疗费用）、政府支出以及医疗保险和非政府组织活动等来源组成。因此，增加癌症治疗的医疗支出是增加市场需求的机会。
-
主要参与者的战略举措
全球范围内，各类疾病的发病率和严重程度都在上升。研究质量的大幅提高和研究机会的增加得益于市场参与者采取的各种战略举措。多年来，他们采取了产品发布、合作、合并、收购等举措，预计将引领和创造更多市场机会。例如，赢创投资于其位于德国哈瑙和多森海姆工厂的黑色素瘤癌症诊断专用产品的短期增长，这些工厂为辉瑞/BioNTech 疫苗提供了四种黑色素瘤癌症诊断产品中的两种。据 Spencer 称，第一批产品已于 2021 年 4 月交付给 BioNTech，比原计划提前了几个月。
限制/挑战
- 黑色素瘤癌症诊断产品的审批和商业化有严格的法规和标准
任何产品在市场上商业化的严格规定对于全球癌症诊断产品制造商而言都是一个巨大的挑战，因为他们有自己的规定和不同的监管程序机构。
制造商批准将产品商业化推向市场。因此，在北美地区，严格的监管政策预计将阻碍癌症诊断市场的发展。
上市许可或 CE 认证的监管要求以及法律法规的应用可能会导致业务发生重大变化或支付罚款，包括可能失去营业执照。遵守这些法律、规则和法规所需的资源和成本相当高。脂质纳米颗粒生产的不同制造挑战
新冠肺炎疫情对北美黑色素瘤癌症诊断市场的影响
COVID-19 对市场产生了积极影响。随着诊断需求的增加，预防性健康检查的需求也很高。因此，COVID-19 对黑色素瘤癌症诊断市场产生了积极影响。
近期发展
- 2022 年 10 月，Quest Diagnostics Incorporated 宣布与 Decode health 合作获取基于生物标记的数据，这些数据有助于减少开发针对不同类型癌症的新型诊断测试和药物靶点的时间和成本。这将有助于该公司在研发领域找到创新路径，并增加该公司在北美市场的存在
- 2022 年 5 月，Myriad Genetics, Inc. 宣布扩大与 Intermountain Healthcare 旗下服务公司 Intermountain Precision Genomics 的战略合作伙伴关系，为该公司不断增长的肿瘤学产品组合添加一项新的液体活检治疗选择测试。这将为精准肿瘤测试提供不断增长的液体活检空间
北美黑色素瘤癌症诊断市场范围
北美黑色素瘤癌症诊断市场分为产品类型、检测类型、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
产品类型
- 仪器
- 耗材及配件
- 其他的
根据类型，北美黑色素瘤癌症诊断市场分为仪器、消耗品和配件以及其他。
测试类型
- 活检
- 影像学检查
- 免疫组织化学 (IHC) 检测
- 生物标志物测试
- 荧光原位杂交 (FISH) 测试
- 比较基因组杂交 (CGH) 测试
- 其他的
根据测试类型，北美黑色素瘤癌症诊断市场分为生物标志物测试、影像学测试、活检、荧光原位杂交 (FISH) 测试、比较基因组杂交 (CGH) 测试、免疫组织化学 (IHC) 测试等。
最终用户
- 医院
- 相关实验室
- 独立诊断实验室
- 诊断成像中心
- 癌症研究机构
- 其他的
根据最终用户，北美黑色素瘤癌症诊断市场分为医院、相关实验室、独立诊断实验室、诊断成像中心、癌症研究机构等。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，北美黑色素瘤癌症诊断市场分为直接招标、零售销售和其他。
黑色素瘤癌症诊断市场区域分析/见解
对北美黑色素瘤癌症市场进行了分析，并按产品类型、测试类型、最终用户和分销渠道提供了市场规模洞察和趋势。
北美黑色素瘤癌症市场包括美国、加拿大和墨西哥等国家。
由于对优质医疗服务的需求不断增长以及对非侵入性检测方法的需求不断增加，美国预计将主导北美黑色素瘤癌症诊断市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场法规变化。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和黑色素瘤癌症诊断市场份额分析
北美黑色素瘤癌症诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对北美黑色素瘤癌症诊断市场的关注有关。
北美黑色素瘤癌症诊断市场的一些主要参与者包括 Nanostring、Thermo Fisher Scientific Inc.、Quest Diagnostics Incorporated、Agilent Technologies, Inc、QIAGEN、Inivata Ltd、F. Hoffman-La Roche Ltd、Abbott、AMLo Biosciences Limited、Myriad Genetics Genetics Inc、Castle Biosciences、DermTech、Michael Diagnostics Ltd、Damae Medical、Skin Analytics、DermLite、DermaSensor、Skyline Dx、Neracare GmbH、VERISKIN INC.、Illumina Inc 和 bioMerieux SA 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
6.2.1 PRODUCT INNOVATION
6.2.2 CONSUMER AWARNESS
6.2.3 A VAST NETWORK OF DISTRIBUTION
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS
6.2.5 OTHERS
6.3 KEY PATIENT ENROLLMENT STRATEGIES
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP
6.3.3 EDUCATE AND COMMUNICATE
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER
7.2 RESTRAINTS
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS
7.4.2 RADIATION RISKS FROM IMAGING TESTS
8 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 ULTRASOUND SYSTEMS
8.2.1.2 MRI SYSTEMS
8.2.1.3 CT SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 PCR INSTRUMENTS
8.2.3.2 CELL PROCESSORS
8.2.3.3 SLIDE STAINING SYSTEMS
8.2.3.4 TISSUE PROCESSING SYSTEMS
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 DNA POLYMERASE KITS
8.3.1.4 OTHERS
8.3.2 PROBES
8.3.2.1 Q FISH
8.3.2.2 FLOW FISH
8.3.2.3 OTHERS
8.3.3 REAGENTS
8.3.3.1 ASSAYS
8.3.3.2 BUFFERS
8.3.3.3 PRIMERS
8.3.3.4 OTHERS
8.3.4 OTHER CONSUMABLES
8.4 OTHERS
9 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 ULTRASOUND
9.2.2 MRI
9.2.3 CHEST X-RAY
9.2.4 LYMPHOSCINTIGRAPHY
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.7 OTHERS
9.3 BIOPSY
9.3.1 OPTICAL BIOPSY
9.3.2 EXCISIONAL BIOPSY
9.3.3 INCISIONAL BIOPSY
9.3.4 SHAVE BIOPSY
9.3.5 PUNCH BIOPSY
9.3.6 OTHERS
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS
9.4.1 S100 PROTEIN FAMILY BIOPSY
9.4.2 MELAN-A
9.4.3 PMEL/PMEL17/SILV/GP100
9.4.4 TYROSINASE
9.4.5 MITF
9.4.6 SM5-1
9.4.7 CSPG4/HMW-MAA
9.5 BIOMARKER TEST
9.5.1 BRAF MUTATION TEST
9.5.2 NRAS MUTATION TEST
9.5.3 CKIT TEST
9.5.4 OTHERS
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS
9.8 OTHERS
10 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 ASSOCIATED LABS
10.4 DIAGNOSTIC IMAGING CENTERS
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES
10.6 CANCER RESEARCH INSTITUTES
10.7 OTHERS
11 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ILLUMINA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BIOMÉRIEUX SA
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 THERMO FISHER SCIENTIFIC INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 AGILENT TECHNOLOGIES, INC.
15.6.1 COMPANY PROFILE
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMLO BIOSCIENCES LIMITED
15.7.1 COMPANY PROFILE
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 CASTLE BIOSCIENCES INC
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 DAMAE MEDICAL
15.9.1 COMPANY PROFILE
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 DERMLITE.
15.10.1 COMPANY PROFILE
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 DERMASENSOR
15.11.1 COMPANY PROFILE
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 DERMTECH
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 INIVATA LTD.
15.13.1 COMPANY PROFILE
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 MICHAEL DIAGNOSTICS LTD
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 MYRIAD GENETICS, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 NANOSTRING
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 NERACARE GMBH
15.17.1 COMPANY PROFILE
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 SKIN ANALYTICS
15.18.1 COMPANY PROFILE
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SKYLINEDX
15.19.1 COMPANY PROFILE
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
15.2 VERISKIN INC.
15.20.1 COMPANY PROFILE
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
15.21 QIAGEN
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 QUEST DIAGNOSTICS INCORPORATED (2022)
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA CONSUMERS & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA HOSPITALS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA ASSOCIATED LABS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA CANCER RESEARCH INSTITUTES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA DIRECT TENDER IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA RETAIL SALES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 50 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 U.S. INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 U.S. PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 U.S. IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 U.S. CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 U.S. KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 U.S. REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 U.S. PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 U.S. BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.S. IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 U.S. MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 CANADA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 CANADA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 CANADA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 CANADA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 CANADA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 CANADA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 CANADA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 CANADA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 CANADA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 CANADA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 MEXICO INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 MEXICO PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 MEXICO IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 MEXICO CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 MEXICO KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 MEXICO REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 MEXICO PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 MEXICO BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 MEXICO IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 MEXICO BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 MEXICO IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 94 MEXICO MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF MELANOMA CANCER AND THE INCREASING AWARENESS REGARDING MELANOMA CANCER ARE EXPECTED TO DRIVE THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 ESTIMATED PREVALENCE OF MELANOMA CANCER IN 2020
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET
FIGURE 15 NUMBER OF NEW CASES IN 2018 IN FEMALES OF ALL AGES
FIGURE 16 AGEING EUROPE POPULATION (IN MILLION)
FIGURE 17 ESTIMATED LIFETIME CARE SPENDING
FIGURE 18 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 23 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 39 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
